YK-11 | 35mg/1,5ml

What is YK-11?

YK-11 is a synthetic compound in the class of selective androgen receptor modulators (SARM), characterized by a structure based on dihydrotestosterone (DHT). Developed to study its influence on muscle mass and androgen activity, YK-11 is positioned as a unique compound that combines androgen modulation with potential inhibition of myostatin. This dual function sets it apart from other SARMs and makes it a subject of heightened scientific interest in the fields of molecular biology and muscle regulation research.

Mechanism of Action of YK-11

YK-11 interacts with androgen receptors, activating specific gene pathways associated with muscle hypertrophy. A notable feature of its mechanism is the ability to increase levels of follistatin—an endogenous protein that suppresses the action of myostatin. Myostatin is a key regulator that limits excessive muscle growth. Through balanced suppression of this mechanism, YK-11 creates conditions for increased muscle protein synthesis while maintaining selectivity toward androgen receptors. This makes it a particularly valuable subject for studies focused on optimizing muscle function and physiology.

Potential Research-Supported Benefits of YK-11

• Enhanced muscle growth through modulation of the androgen receptor;
• Increased production of follistatin and corresponding suppression of myostatin;
• Improved muscle density and a pronounced anabolic response;
• Potential improvement in strength metrics and recovery processes;
• Maintenance of relative tissue selectivity with minimal impact on other organs.

These effects are the subject of in-depth laboratory analyses and studies aimed at better understanding the molecular mechanisms involved in muscle regulation.

Comparison of YK-11 with Other SARMs

YK-11 differs from other selective androgen receptor modulators (SARMs) through its unique DHT-based structure and its ability to influence follistatin—an endogenous inhibitor of myostatin. This additional activity places it in a separate category when compared with classical SARMs such as Ostarine (MK2866), RAD-140, and S23.

Compared with Ostarine, YK-11 is considered to have a significantly stronger anabolic potential, but with higher requirements for control and monitoring. While Ostarine is preferred for longer and lighter research protocols, YK-11 is primarily used in shorter cycles with an intensive focus on muscle growth.

In comparison with RAD-140, which is also known for a strong anabolic effect, YK-11 has the additional mechanism of increasing follistatin—an effect that RAD-140 does not possess. This gives YK-11 an advantage in research targeting maximal limitation of myostatin activity—a factor that hinders muscle growth.

Relative to S23, which is extremely potent but associated with suppression of endogenous testosterone, YK-11 offers a less conventional yet highly effective approach to anabolic processes. Both compounds require attention to dosing, but YK-11 shows potential for unique results in conditions where hypertrophy beyond standard boundaries is sought.

Due to its complexity and specific mechanism, YK-11 is often applied in advanced laboratory protocols when a combined effect from androgen stimulation and myostatin regulation is desired.

Dosage and Use of YK-11 in Research Protocols

Recommended research scheme: 3 units once daily, in the course of 4–6 weeks, followed by a 2–4 week off period.

1 unit = 23.33mcg.

Total amount in pen: 150 units

Possible Side Effects of YK-11

Despite the interest in its properties, YK-11 should be considered with attention regarding its safety profile. Based on available research data, possible adverse reactions include:

• Suppression of natural testosterone production;
• Androgenic manifestations with more prolonged use;
• Insufficient data on effects during long-term use.

Adhering to optimal dosing and controlling the duration of application play a key role in limiting the manifestation of side effects.

Disclaimer

For research use only. Not for human consumption.